Digibus (c): results from the first self-driving shuttle trial on a public road in Austria

被引:33
|
作者
Rehrl, Karl [1 ]
Zankl, Cornelia [1 ]
机构
[1] Salzburg Res Forsch Gesellsch mbH, Jakob Haringer Str 5, A-5020 Salzburg, Austria
关键词
Automated driving; Self-driving shuttle; Public road trial; Rural area; First/last mile;
D O I
10.1186/s12544-018-0326-4
中图分类号
U [交通运输];
学科分类号
08 ; 0823 ;
摘要
From April to November 2017, the non-profit research organisation Salzburg Research conducted the "Digibus (c) 2017" trial, the first trial of a self-driving shuttle on a public road in Austria. The shuttle from the French company Navya Tech has been tested on a 1.4-km long track in the village of Koppl, which is situated approximately ten kilometres east from the City of Salzburg. The trial in Koppl was one of the first trials worldwide on public roads with mixed traffic in a rural area. The focus of this trial was on the real-world evaluation of a self-driving shuttle for bridging the first/last mile in public transport. From April to November 2017, 240 test drives with 874 passengers covering 341 test kilometres have been conducted. Results show that the technology is ready for testing, but there is still a long way to go for driverless operation, especially in mixed traffic scenarios. The work describes the trial setting, the test route, the process of deploying the shuttle, experiences collected during the trial as well as results from a passenger survey. The accompanying passenger survey with 294 participants revealed high acceptance and a good feeling of safety.
引用
收藏
页数:11
相关论文
共 45 条
  • [41] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 653 - 653
  • [42] Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single-arm, multicenter, phase II clinical trial-Update results from ALTER-C001
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [43] Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial
    Jin, Y.
    Han, Y.
    Zhang, L.
    Jin, Y.
    Sun, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S546 - S547
  • [45] VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
    Oaknin, A.
    Gladieff, L.
    Martinez-Garcia, J.
    Villacampa, G.
    Takekuma, M.
    De Giorgi, U. F. F.
    Lindemann, K.
    Woelber, L.
    Colombo, N.
    Duska, L. R.
    Leary, A.
    Godoy Ortiz, A.
    Nishio, S.
    Angelergues, A.
    Rubio Perez, M. J.
    Farinas Madrid, L.
    Yamaguchi, S.
    Lorusso, D.
    D'Hondt, V.
    Randall, L.
    ANNALS OF ONCOLOGY, 2023, 34 (12) : 1198 - 1200